<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recurrent pericarditis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recurrent pericarditis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Recurrent pericarditis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yehuda Adler, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Massimo Imazio, MD, FESC, FHFA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jae K Oh, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Recurrent pericarditis is a common and often vexing problem for pericardial disease specialists as well as primary care clinicians. The term refers to a syndrome in which symptoms of acute pericarditis recur after the initial episode.</p><p>Recurrent pericarditis, including its definition, proposed pathogenesis, clinical manifestations, diagnosis, and treatment, will be reviewed here. The clinical manifestations, diagnosis, and treatment of patients with an initial attack of acute pericarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The time course of symptoms after treatment of acute pericarditis is variable [<a href="#rid1">1-8</a>]. Although most patients experience resolution of symptoms of acute pericarditis with therapy, some patients have persistent or recurrent symptoms. The following terms are used to define these differing clinical responses to therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute pericarditis</strong> is a condition lasting &lt;4 to 6 weeks. Symptoms of acute pericarditis may recur at any time following cessation of acute symptoms  (<a class="graphic graphic_table graphicRef64302" href="/z/d/graphic/64302.html" rel="external">table 1</a>), typically weeks to months later [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent pericarditis</strong> occurs when symptoms of acute pericarditis return after a symptom-free interval of least four to six weeks [<a href="#rid6">6,9</a>]. Four to six weeks has been established as the minimum required symptom-free interval as it represents the typical duration of antiinflammatory therapy (including taper).</p><p></p><p class="bulletIndent1">The recurrence rate for acute pericarditis is not well established, but may be as high as 15 to 30 percent in patients with idiopathic acute pericarditis not treated with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid2">2,7,10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incessant pericarditis</strong> is defined as occurring when symptoms persist for greater than four to six weeks up to three months without a sustained remission [<a href="#rid6">6</a>]. This includes recurrence of symptoms after a symptom-free interval of less than four to six weeks after the acute episode. Such recurrences often occur during attempted drug weaning, particularly following glucocorticoid therapy, occurring less commonly following nonsteroidal antiinflammatory drug (NSAID) use. Incessant pericarditis is associated with an increased risk of developing constrictive pericarditis within six months from symptom onset [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic pericarditis</strong> is defined as occurring when symptoms persist for greater than three months [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Observational studies suggest that most cases of recurrent pericarditis are caused by an autoimmune disorder, but a minority of cases may be due to an infection (most likely viral, which may be chronic infection, reinfection, or new infection).</p><p>Evidence supporting an immunopathologic process includes a latent period that commonly lasts for months and similarities to other autoimmune conditions, including the presence of autoantibodies and responsiveness to glucocorticoid and other immunosuppressive therapies [<a href="#rid13">13,14</a>]. (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p>It has been shown that a substantial number of cases of recurrent pericarditis display features of systemic inflammation (eg, fever and/or elevation of C-reactive protein at each episode). In such cases, recurrent pericarditis may share some features of autoinflammatory diseases, a group of disorders affecting the immune system in adults and children and often accompanied by signs of inflammation (recurrent fever, serositis, arthralgias, myalgias, elevated C-reactive protein). Indeed, in up to 10 percent of cases, a monogenic autoinflammatory diseases may be the cause of recurrences [<a href="#rid15">15,16</a>].</p><p>In some patients with recurrent pericarditis, cytokines such as interleukin (IL) 6, IL-8, and interferon gamma have been detected in the pericardial fluid but not in sera [<a href="#rid17">17</a>]. This distribution of cytokines suggests a local inflammatory process. These features of immune or inflammatory disease suggest a role for immune therapies such as IL-1 inhibitor, for patients who fail to respond to NSAIDs, glucocorticoids, and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>. (See  <a class="medical medical_review" href="/z/d/html/16578.html" rel="external">"Pericardial involvement in systemic autoimmune diseases"</a> and <a class="local">'Inflammatory phenotype'</a> below and <a class="local">'Pharmacologic therapy'</a> below.)</p><p>An infectious or systemic etiology cannot usually be identified using standard laboratory techniques. In one study of recurrent pericarditis, investigators performed extensive studies to evaluate suspected recurrent pericarditis, including pericardioscopy, multiple epicardial biopsies, and polymerase chain reaction [<a href="#rid18">18</a>]. Epicardial biopsy was performed during pericardioscopy and targeted at regions that appeared abnormal. The authors reported a higher prevalence of infection or reinfection (approximately 23 percent) than reported in other studies [<a href="#rid7">7,18</a>].</p><p>Familial factors may be important in some cases. A cluster of recurrent pericarditis has been described in five members of a family of German and Danish ancestry [<a href="#rid19">19</a>]. It was suggested that this might represent familial disease with possible autosomal dominant inheritance.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H2801226"><span class="h2">Key features</span><span class="headingEndMark"> — </span>Recurrent pericarditis is manifested by recurrence of the symptoms and signs of acute pericarditis  (<a class="graphic graphic_table graphicRef64302" href="/z/d/graphic/64302.html" rel="external">table 1</a>) after a symptom-free interval of at least four to six weeks. The presenting symptoms of recurrent pericarditis are generally similar to those for acute pericarditis, although the presenting symptoms may not be consistent for each individual patient and are frequently less intense during recurrences [<a href="#rid20">20</a>]. The predominant feature of recurrent pericarditis is usually pleuritic chest pain (often sharp, worse when lying flat, and alleviated when leaning forward), which may follow exertion. Some patients may also report dyspnea or malaise. Other clinical manifestations of acute pericarditis are often absent.</p><p class="headingAnchor" id="H2536993906"><span class="h2">Other features and complications</span><span class="headingEndMark"> — </span>Other clinical features and complications, such as pericardial rubs, pericardial effusion, and cardiac tamponade, are less common with subsequent episodes, and cardiac tamponade is a rare complication even in patients who had cardiac tamponade during the initial episode [<a href="#rid3">3,9,13,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p>Constrictive pericarditis is an uncommon complication, estimated as occurring in less than 1 percent of patients with recurrent pericarditis [<a href="#rid6">6,9,13,19,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p>Recurrent pericarditis is generally <strong>not</strong> associated with ventricular systolic dysfunction or heart failure [<a href="#rid9">9,13</a>].</p><p class="headingAnchor" id="H2801668"><span class="h2">Time course</span><span class="headingEndMark"> — </span>Symptoms of recurrent pericarditis occur at a variable time after the initial attack, but usually within 18 months [<a href="#rid11">11,23</a>]. By definition, recurrent pericarditis occurs after an at least four- to six-week symptom-free interval. (See <a class="local">'Definitions'</a> above.)</p><p>Most patients with recurrent pericarditis feel well between attacks, although some patients have a more persistent or chronic course [<a href="#rid7">7,8</a>]. The number of recurrences and the intervals between them vary considerably among patients, with 40 to 50 percent of patients who experience a recurrence having only one to two recurrences, which usually occur over several months to a few years following the initial episode [<a href="#rid9">9,23,24</a>]. However, some reports have shown that the period of time prior to a recurrence, and the duration of treatment required to effectively treat recurrences, may extend for years or, in rare cases, decades [<a href="#rid2">2,3,13</a>]. Although not well documented in the literature, the clinical experience of our contributors has been that heavy exertion prior to complete resolution of pericardial inflammation may result in recurrent chest pain. (See <a class="local">'Activity restriction'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Predictors of recurrence</span><span class="headingEndMark"> — </span>No presenting clinical feature of an initial episode of acute pericarditis reliably predicts recurrence. However, a positive response to initial <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or other NSAID therapy is associated with a reduced risk of recurrence, while initial therapy with a glucocorticoid is associated with a greater risk of recurrence.</p><p>An observational study of patients with presumed idiopathic acute pericarditis identified an association between lack of response to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or other NSAID therapy and risk of recurrence [<a href="#rid10">10</a>]. Compared with responders, those who did not respond to aspirin or other NSAID therapy had a much higher rate of recurrent pericarditis (61 versus 10 percent) and of pericardial constriction (9.1 versus 0.5 percent). (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Nonsteroidal antiinflammatory drugs'</a>.)</p><p>Glucocorticoid therapy as the initial treatment for acute pericarditis appears to promote recurrence, as suggested by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>The best data come from the COPE trial of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy in patients with a first episode of acute pericarditis in which glucocorticoids were given only when <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> was contraindicated or not tolerated [<a href="#rid11">11</a>]. Glucocorticoid use was a significant predictor of recurrence (odds ratio [OR] 4.3, 95% CI 1.2-15.3), an effect that has been postulated to be due to promotion of viral replication [<a href="#rid25">25</a>]. The COPE trial also showed that colchicine therapy markedly reduces the rate of recurrence. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Colchicine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were noted in the CORE trial of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy in patients with recurrent pericarditis by the same investigators [<a href="#rid24">24</a>]. Previous glucocorticoid use was an independent risk factor for further recurrences (OR 2.9, 95% CI 1.1-8.3).</p><p></p><p class="headingAnchor" id="H2235325"><span class="h2">Initial test findings</span><span class="headingEndMark"> — </span>Initial testing including blood work, chest radiography, and electrocardiography can support the diagnosis, but normal findings are common and abnormal findings are often nonspecific. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p class="headingAnchor" id="H2483185337"><span class="h3">Laboratory findings</span><span class="headingEndMark"> — </span>Since pericarditis is an inflammatory disease, laboratory signs of inflammation are common in patients with recurrent pericarditis. These include elevations in the white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), and serum C-reactive protein (CRP) concentration. While elevation in these markers supports the diagnosis and has implications for prognosis and possibly for treatment, these markers are neither sensitive nor specific for recurrent pericarditis [<a href="#rid26">26,27</a>]. Absence of elevation in WBC count, ESR, and/or CRP does not exclude the diagnosis of recurrent pericarditis.</p><p class="headingAnchor" id="H2235344"><span class="h3">Electrocardiogram</span><span class="headingEndMark"> — </span>In recurrent pericarditis, changes on the electrocardiogram (ECG) are less specific than for acute pericarditis. Only rarely is ST elevation identified, and more common findings include nonspecific ST-segment and T-wave changes (ie, T-wave inversion or flattening). Given these observations, it is not possible to describe specific stages of ECG changes for recurrent pericarditis as in acute pericarditis.</p><p>ECG changes associated with an initial attack of acute pericarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Electrocardiogram'</a>.)</p><p class="headingAnchor" id="H2235479"><span class="h3">Chest radiograph</span><span class="headingEndMark"> — </span>A chest radiograph is not required in patients with suspected recurrent pericarditis but may be performed as part of an evaluation for dyspnea. The chest radiograph is often normal in patients with recurrent pericarditis unless there is an associated pericardial effusion. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H2802311"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3282280740"><span class="h2">Approach to diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect recurrent pericarditis</strong> – Recurrent pericarditis should be suspected in a patient with a prior episode of acute pericarditis who develops characteristic pleuritic chest pain. Recurrent or incessant pericarditis may also be suspected in a patient with prior acute pericarditis who presents with persistent fever and pericardial effusion or new unexplained cardiomegaly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial testing</strong> – For patients with suspected recurrent pericarditis, testing should include an ECG, focused laboratory studies searching for evidence of inflammation (white blood cell [WBC] count, erythrocyte sedimentation rate [ESR], and C-reactive protein [CRP]), and an echocardiogram. Results of diagnostic testing can support a diagnosis of recurrent pericarditis, but no single test definitively makes or excludes the diagnosis. (See <a class="local">'Initial test findings'</a> above and <a class="local">'Diagnostic criteria'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiogram</strong> – Transthoracic echocardiography is performed in patients with suspected recurrent pericarditis. While the echocardiogram is frequently normal, it is helpful in identifying an associated pericardial effusion (in this setting, rarely associated with cardiac tamponade) and signs of constrictive pericarditis (an uncommon complication). (See <a class="local">'Other features and complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced imaging </strong>is indicated for only selected patients when clinical evaluation and initial testing are inconclusive. For patients with recurrent chest pain after prior acute pericarditis with no signs of pericardial inflammation on initial testing, cardiovascular magnetic resonance (CMR) or computed tomography (CT) may be helpful, as noted by major society guidelines [<a href="#rid14">14,28</a>]. In such cases, the diagnosis of recurrence can rely on identification of pericardial edema and late gadolinium enhancement (LGE) on CMR [<a href="#rid26">26,28,29</a>] or detection of pericardial thickening and contrast-enhancement on CT. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Pericardial disease'</a>.)</p><p></p><p class="bulletIndent1">Imaging can also be useful to monitor disease activity and predict the outcome and probability of remission [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H2704579797"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The following criteria are applied in identifying clinical syndromes of recurrent pericarditis (see <a class="local">'Definitions'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent pericarditis is diagnosed in a patient with a prior episode of acute pericarditis who develops recurrent symptoms (typically pleuritic chest pain) and at least one sign of pericardial inflammation (fever, pericardial rub, characteristic ECG changes, new or worsening pericardial effusion, elevation of an inflammatory marker [WBC count, ESR, or CRP], or evidence of pericardial inflammation on CMR or CT) after an at least four- to six-week symptom-free interval  (<a class="graphic graphic_table graphicRef64302" href="/z/d/graphic/64302.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incessant pericarditis is diagnosed if diagnostic criteria for recurrent pericarditis are present, but the symptom-free interval is &lt;4 to 6 weeks and the total duration of symptoms is three months or less.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pericarditis is diagnosed in a patient with diagnostic criteria for recurrent pericarditis with a symptom-free interval of &lt;4 to 6 weeks and a total duration of symptoms greater than three months.</p><p></p><p>The approach to the evaluation of the cause of recurrent pericarditis is the same as for evaluation of the cause of the initial episode of acute pericarditis, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H434481202"><span class="h2">Inflammatory phenotype</span><span class="headingEndMark"> — </span>Patients with recurrent pericarditis may present with an inflammatory or noninflammatory phenotype. An inflammatory phenotype is characterized by the presence of one or more of signs of an inflammatory process when presenting with a recurrence: fever, elevated CRP, elevated WBC count, elevated ESR, pericardial LGE on CMR, or pericardial contrast enhancement on CT. Patients presenting without any of these signs of inflammation have a noninflammatory phenotype.</p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of recurrent pericarditis is similar to that of the initial episode of acute pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). Most patients with recurrent pericarditis can be managed effectively with medical therapy alone, and outpatient management is feasible in almost all cases [<a href="#rid14">14,23,24</a>]. Hospitalization should be limited to patients with high-risk features, as in acute pericarditis  (<a class="graphic graphic_algorithm graphicRef114845" href="/z/d/graphic/114845.html" rel="external">algorithm 1</a>) [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p>For patients with idiopathic or viral recurrent pericarditis, treatment focuses on control of symptoms as described here. For patients with recurrent pericarditis from other causes, symptomatic therapy is accompanied by specific therapy for the underlying disorder. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H5172638"><span class="h2">General measures</span></p><p class="headingAnchor" id="H7"><span class="h3">Communication with the patient</span><span class="headingEndMark"> — </span>Effective communication with and education of the patient is important when managing recurrent pericarditis, as the condition can be prolonged and frustrating with disabling symptoms, and management requires extended adherence to therapies. It is important to explain to the patient the nature of the disease, the likely course, and the treatment alternatives. Specific features of the disease that should be emphasized include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>After successful treatment of a recurrence, further recurrences are possible, and may repeat, at variable intervals, for up to several years. (See <a class="local">'Time course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent episodes are not usually caused by reinfection, even among patients whose first illness was viral. It is reasonable to reassure patients that the disease eventually resolves in most cases, nearly always with no permanent sequelae.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although both are uncommon complications, the symptoms and signs of cardiac tamponade and constrictive pericarditis should be reviewed with the patient. (See  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a> and  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H2234732"><span class="h3">Activity restriction</span><span class="headingEndMark"> — </span>Strenuous physical activity may trigger worsening of symptoms; therefore, such activity should be avoided until symptom resolution. Athletes should not participate in competitive sports until there is no longer evidence of active disease (eg, resolution of symptoms and normalization of inflammatory biomarkers). Although supporting evidence is not available, we ask patients to restrict exertion to a level necessary to perform domestic tasks and undertake sedentary work [<a href="#rid9">9</a>], as for the initial episode. (see  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Activity restriction'</a>)</p><p>An observational study found that improved control of heart rate with the use of beta blockers was associated with a higher rate of early resolution of symptoms [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H4226550833"><span class="h2">Pharmacologic therapy</span></p><p class="headingAnchor" id="H2766805048"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>The following approach is for nonpregnant patients with recurrent pericarditis. Doses are described in the table  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>).</p><p>Management of pericarditis during pregnancy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4934.html" rel="external">"Management of pericardial effusion and acute pericarditis during pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – For most patients with recurrent pericarditis, we recommend initial combination therapy with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> plus either an NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, rather than NSAID alone. (See <a class="local">'Colchicine'</a> below and <a class="local">'NSAID or aspirin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid</strong><strong> plus </strong><strong>colchicine</strong> – For patients with recurrent pericarditis with persistent symptoms on <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> plus an NSAID (or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) or who have a contraindications to NSAID and aspirin therapy, we suggest treatment with glucocorticoid therapy plus colchicine. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triple therapy</strong> – For patients with persistent symptoms on dual therapy with glucocorticoid therapy plus <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, we suggest addition of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy (triple therapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fourth-line therapy</strong> – For patients with recurrent pericarditis with persistent symptoms despite third-line therapy, we treat based upon whether an inflammatory phenotype is present. In this setting the potential benefits and risks of immune therapy, and of pericardiectomy as an alternative, are considered. (See <a class="local">'Role of pericardiectomy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an inflammatory phenotype (see <a class="local">'Inflammatory phenotype'</a> above), we suggest an interleukin (IL) 1 inhibitor (<a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a> or <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>). (See <a class="local">'Interleukin 1 inhibitors'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a noninflammatory phenotype, options include intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>; preferred for patients with an autoimmune disorder) and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (preferred for patients with no identified autoimmune disorder). (See <a class="local">'Other immune therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">NSAID or aspirin</span><span class="headingEndMark"> — </span>An NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is a key component of initial therapy for recurrent pericarditis (as for acute pericarditis) [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients without a contraindication to NSAID</strong> – For most patients with recurrent pericarditis, we use an NSAID, with the duration of therapy (typically full-dose for at least one to two weeks for symptom control followed by two or more weeks of tapered dosing) guided by the persistence of symptoms and the normalization of inflammatory biomarkers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients taking </strong><strong>aspirin</strong><strong> as an antiplatelet agent</strong> – For patients taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as an antiplatelet agent (including patients post-myocardial infarction) we generally avoid NSAIDs, since <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> and some other NSAIDs can interfere with the antiplatelet effect of low-dose aspirin. Most patients can be effectively treated with daily aspirin doses lower than 3000 mg  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). Management of pericarditis associated with myocardial infarction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4937.html" rel="external">"Pericardial complications of myocardial infarction", section on 'Management of PIP'</a>.)</p><p></p><p>Gastrointestinal protection should be provided during NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy, as described separately. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Nonsteroidal antiinflammatory drugs'</a> and  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p>The different NSAIDs are probably equally effective but must be given in appropriate antiinflammatory doses. Numerous NSAID regimens are available for treatment of recurrent pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). Given its widespread availability, relative safety, and low cost, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> (600 to 800 mg orally three times daily) is typically the first choice for therapy. <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">Indomethacin</a> (50 mg three times daily) is usually reserved for more severe cases and when first-line NSAIDs fail. The patient's prior experience can provide a useful guide for deciding among agents. Many patients with recurrent pericarditis have tried a number of different NSAIDs at different times. If a patient reports that a specific drug has proven effective, it is reasonable to use that agent.</p><p>If the initial response to NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy is not satisfactory, the dose should be increased (up to the recommended daily maximum dose), or an alternative antiinflammatory agent used, until an adequate response is achieved. The NSAID or aspirin should be administered as three doses daily to optimize symptom control until symptom resolution. This approach should be continued until it is clear that NSAIDs have failed to control the syndrome, especially the pain, or that the drugs are not tolerated. A more extensive discussion of NSAID regimens is presented separately. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'NSAID dosing'</a>.)</p><p>Following symptom resolution, the NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be slowly tapered to reduce the subsequent recurrence rate  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>) [<a href="#rid10">10,11,23,24,32,33</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Colchicine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> is a key component of therapy for recurrent pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>) [<a href="#rid14">14</a>]. The use of colchicine with an NSAID can reduce or eliminate the need for glucocorticoids in patients with recurrent pericarditis. Colchicine should be prescribed in two doses daily rather than a single dose to reduce the risk of gastrointestinal intolerance and improve patient compliance [<a href="#rid32">32-34</a>].</p><p>The effectiveness of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> in patients with recurrent pericarditis has been evaluated in three randomized, placebo-controlled trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In the CORE trial, 84 consecutive patients with a first episode of recurrent pericarditis were randomly assigned to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone or in combination with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (1 to 2 mg on the first day, followed by 0.5 once or twice daily for six months) [<a href="#rid24">24</a>]. Colchicine therapy was associated with a marked and significant reduction in the primary endpoint of the rate of recurrence at 18 months (24 versus 51 percent), and a significant reduction in the secondary endpoint of symptom persistence at 72 hours (10 versus 31 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CORP trial, 120 consecutive patients with a first episode of recurrent pericarditis were randomly assigned to conventional antiinflammatory therapy alone (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, or <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) or in combination with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (1 to 2 mg on the first day, followed by 0.5 once or twice daily for six months) [<a href="#rid35">35</a>]. Treatment with colchicine significantly reduced the primary endpoint of first recurrence at 18 months (24 versus 55 percent with placebo; absolute risk reduction [ARR] 31 percent, 95% CI 13-46), in addition to improving several secondary outcomes, including persistent symptoms at 72 hours (23 versus 53 percent with placebo; ARR 30 percent, 95% CI 13-45).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CORP-2 trial, 240 patients with two or more episodes of recurrent pericarditis were randomly assigned to placebo or <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (six months of therapy with 0.5 mg twice daily for patients &gt;70 kg <strong>or</strong> 0.5 mg once daily for patients ≤70 kg or who were intolerant of twice daily dosing) in addition to conventional antiinflammatory therapy (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, or <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) [<a href="#rid36">36</a>]. Compared with placebo, patients treated with colchicine experienced significantly fewer recurrences (26 [22 percent] versus 51 [43 percent] in patients receiving placebo; relative risk [RR] 0.49, 95% CI 0.24-0.65) as well as significantly fewer symptoms at 72 hours (19 versus 44 percent) and at one week (17 versus 41 percent) with no significant difference in adverse events between the two groups.</p><p></p><p>A meta-analysis identified similar efficacy in reducing the recurrence rate of pericarditis in patients with acute pericarditis (five randomized controlled trials; RR 0.46, 95% CI 0.36-0.58) and recurrent pericarditis (the three randomized trials described above; RR 0.48, 95% CI 0.36-0.63) [<a href="#rid37">37</a>]. Data from seven of these trials showed that gastrointestinal intolerance was the most commonly reported adverse effect of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (RR 1.42, 95% CI 1.05-1.92).</p><p>The use of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> in the treatment of pericarditis and prevention of recurrence is an <strong>off-label use</strong> of the medication. Although low doses of colchicine (0.6 to 1.2 mg per day) have been safe in most patients even when given continuously over decades, there are uncommon (&lt;1 percent) possible side effects to be considered (eg, bone marrow suppression, hepatotoxicity, and muscle toxicity) beyond the well-known gastrointestinal side effects (5 to 10 percent). Chronic kidney disease leading to increased plasma colchicine levels appears to be the major risk factor for side effects. Patient compliance may improve if a loading dose is avoided.</p><p class="headingAnchor" id="H10"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoid therapy is generally a second- or third-line therapy for recurrent pericarditis unless there is a specific indication (systemic inflammatory disease requiring glucocorticoid therapy or pregnancy after week 20), as many patients can be successfully treated without resorting to such therapy [<a href="#rid14">14</a>]. Glucocorticoid use should be limited to selected patients given its potential adverse effects, particularly with prolonged use. Observational studies suggest that glucocorticoid therapy may increase the risk of recurrence [<a href="#rid11">11,24,25,38-40</a>], even after multiple recurrences [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/4934.html" rel="external">"Management of pericardial effusion and acute pericarditis during pregnancy", section on 'Management'</a>.)</p><p>Glucocorticoids are an option for the following subsets of patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who fail combination therapy with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and NSAIDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with intolerance or contraindications to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or NSAIDs (eg, pregnant patients at gestational week 20 or later). (See  <a class="medical medical_review" href="/z/d/html/4934.html" rel="external">"Management of pericardial effusion and acute pericarditis during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with certain systemic autoimmune disorders (eg, dermatomyositis and polymyositis) that are treated with glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/16578.html" rel="external">"Pericardial involvement in systemic autoimmune diseases"</a>.)</p><p></p><p class="headingAnchor" id="H172171"><span class="h4">Our approach to glucocorticoid use</span><span class="headingEndMark"> — </span>If glucocorticoid therapy is indicated, the potential benefit and harms should be discussed with the patient. The patient should also be informed that once a glucocorticoid course has been completed, the aim is to taper the dose and finally discontinue therapy, particularly given concerns that glucocorticoids may perpetuate rather than abolish recurrences. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p>For patients who require glucocorticoid therapy for recurrent pericarditis, we use moderate initial dosing (eg, 0.2 to 0.5 mg/kg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) followed by a slow taper (rather than high doses with a rapid taper)  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). We generally add <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> during glucocorticoid therapy and continue colchicine for four weeks or more after glucocorticoid discontinuation (ie, with an overall length of treatment of three months for acute pericarditis, six months in recurrent cases). This approach is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Our approach to glucocorticoid dosing'</a>.)</p><p>There are conflicting data, mostly derived from observational studies, regarding the optimal dosing and tapering of glucocorticoid therapy when used to treat pericarditis. Although high doses of glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day) have been recommended in the European Society of Cardiology (ESC) guidelines, use of lower doses (eg, prednisone 0.2 to 0.5 mg/kg/day) may be equally efficacious with a reduced risk of side effects, which have been reported in up to 25 percent of patients treated with high doses [<a href="#rid14">14</a>]. Common mistakes are to use too low a dose and, more often, to taper the dose too rapidly [<a href="#rid41">41</a>].</p><p>If symptoms recur, every effort should be made not to increase or reinstitute glucocorticoids but instead control symptoms with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or an NSAID. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p>Guidelines recommend osteoporosis prevention when using glucocorticoids, an issue often neglected in clinical practice. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Intrapericardial glucocorticoid</span><span class="headingEndMark"> — </span>Although supporting evidence is limited, for selected patients with recurrent pericarditis, intrapericardial glucocorticoid therapy is a potential option to achieve high local glucocorticoid concentrations and maintain efficacy while minimizing systemic toxicity. The 2015 ESC guidelines discuss that intrapericardial glucocorticoid therapy may be considered [<a href="#rid14">14</a>]. Such therapy may be considered as a last resort in cases with severe side effects related to systemic use. However, in our view, the utility of such an approach requires further investigation.</p><p>In a review of 84 patients with recurrent or persistent autoreactive pericarditis with effusion, pericardiocentesis with antibiotic prophylaxis was followed by intrapericardial administration of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> (300 to 600 mg/m<sup>2</sup> given in 100 mL of isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at body temperature) as a single injection and then residual pericardial fluid was drained at 24 hours; maintenance therapy consisted of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (0.5 mg three times daily) for six months [<a href="#rid7">7</a>]. This regimen led to symptomatic improvement and prevented recurrence in 90 percent of patients at three months and 84 percent at one year. Most relapses were asymptomatic and only symptomatic large effusions were retreated using the higher triamcinolone dose. Transient cushingoid symptoms developed in 13 and 30 percent of patients given 300 and 600 mg/m<sup>2</sup>, respectively.</p><p>There are technical considerations that may limit the usefulness of intrapericardial therapy. If the patient has a large or moderate sized pericardial effusion, intrapericardial therapy is straightforward. This is usually accomplished via intrapericardial catheter following drainage of the pericardial effusion. If the patient has a small or no pericardial effusion, pericardioscopy must be performed to utilize this form of treatment. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Pericardial fluid analysis and biopsy'</a>.)</p><p class="headingAnchor" id="H1747227731"><span class="h3">Interleukin 1 inhibitors</span><span class="headingEndMark"> — </span>Evidence from randomized trials and observational studies supports the use of IL-1 inhibitor (<a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a> or <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>) for patients with recurrent pericarditis. We use these agents as fourth-line therapy in patients with an inflammatory phenotype (see <a class="local">'Inflammatory phenotype'</a> above). Use of rilonacept or anakinra may be especially helpful for glucocorticoid- or colchicine-dependent patients with an inflammatory phenotype [<a href="#rid42">42-46</a>].</p><p>Withdrawal of IL-1 inhibitor is often followed by recurrences that may require the reintroduction of the drug but are generally responsive to medical therapies without requiring the use of glucocorticoids [<a href="#rid47">47</a>]. The optimal duration of therapy is unknown, although it is probably at least six months or longer [<a href="#rid48">48</a>].</p><p><a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">Rilonacept</a> is a fusion protein that functions as an IL-1 alpha and IL-1 beta cytokine trap. Rilonacept promoted rapid resolution of symptoms and reduced risk of recurrence in a randomized trial enrolling 86 adults and adolescents (mean age 44.7 years) with recurrent pericarditis [<a href="#rid49">49</a>]. Pain resolution or near-resolution occurred at a median of five days and C-reactive protein (CRP) normalization at a median of seven days. Rilonacept was administered by subcutaneous injection as a loading dose of 320 mg (or 4.4 mg per kg of body weight in patients &lt;18 years of age), followed by weekly maintenance doses of 160 mg (or 2.2 mg per kg in patients &lt;18 years of age). After the 12-week run-in period, 61 patients were randomly assigned to weekly rilonacept or placebo. At the median time to first recurrence in the placebo group (8.6 weeks), pericarditis recurrence occurred in 23 of 31 patients (74 percent) in the placebo group compared to 2 of 30 patients (7 percent) in the rilonacept group. Four patients had adverse events leading to discontinuation of rilonacept during the run-in period. The most common adverse events were injection-site reactions and upper respiratory tract infections. The FDA approved the use of rilonacept to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older in March 2021 [<a href="#rid50">50</a>].</p><p><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a> is a recombinant IL-1 receptor antagonist that reduced the risk of further recurrences in patients with recurrent pericarditis in a small randomized trial and in observational studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In the AIRTRIP trial, 21 patients with at least three episodes of recurrent pericarditis (who also had elevated CRP levels, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> resistance, and glucocorticoid dependence) were treated with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> (2 mg/kg up to 100 mg daily maximum) for two months [<a href="#rid51">51</a>]. After two months, and following resolution of pericarditis symptoms, patients were randomized in a double-blind fashion to continue anakinra (11 patients) or switch to placebo (10 patients) for six months or until symptoms recurred. After a median follow-up of 14 months, patients in the anakinra group had significantly fewer recurrences (18 versus 90 percent) and greater symptom-free survival compared with patients receiving placebo. However, 20 of 21 patients receiving anakinra experienced a side effect (primarily local skin reactions, although herpes zoster, elevated liver transaminases, and optic neuropathy were also reported), compared with none of the patients receiving placebo. Patients treated with anakinra were able to wean off of glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective review of 13 patients with recurrent pericarditis refractory to traditional therapy, all 13 patients had at least partial resolution of symptoms following treatment with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, with 11 of 13 patients remaining symptom-free and off of other therapies (NSAIDs, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and glucocorticoids) at median follow-up of 17 months [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an international registry of glucocorticoid-dependent and colchicine-resistant recurrent pericarditis (IRAP registry), which included 224 patients (mean age 46 years, 75 percent idiopathic, 91 percent with elevated CRP, 88 percent with pericardial effusion) with a median duration of disease of 17 months (interquartile range 9 to 33), significant reductions were seen in pericarditis recurrence (from 2.3 to 0.4 recurrences per patient per year) and glucocorticoid use (from 80 percent to 27 percent) following six months of therapy with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, with no serious adverse events reported [<a href="#rid52">52</a>].</p><p></p><p>Scant evidence is available on use of <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> (an immunoglobulin G1 monoclonal antibody against IL-1 beta that blocks binding to the IL-1 receptor complex) for treatment of recurrent pericarditis. Case reports describe use of this treatment in patients with pericarditis with or without associated rheumatologic disorders [<a href="#rid53">53,54</a>]. Canakinumab has been generally less efficacious to control pericarditis, probably because of specific IL-1 beta blockade instead of the combined inhibition of both IL-1 alpha and beta with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> and <a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a> [<a href="#rid55">55</a>].</p><p>A phase II/III study with an IL-1 inhibitor, goflikicept, has shown similar efficacy to treat idiopathic recurrent pericarditis [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Other immune therapy</span><span class="headingEndMark"> — </span>Fourth-line agents for patients with a noninflammatory phenotype include <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (preferred for patients with an autoimmune disorder) and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (preferred for patients with no identified autoimmune disorder). (See <a class="local">'Our approach'</a> above.).</p><p>The 2015 ESC guidelines include recommendations for <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg/day to be slowly uptitrated) and human <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (400 to 500 mg/kg/day IV for five days, with repeated cycles as needed according to the clinical response).</p><p>Limited evidence is available for these therapies. In an observational study of 46 patients with idiopathic recurrent pericarditis, patients with recurrent pericarditis treated with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> had a low rate of recurrence and those that were glucocorticoid-dependent were able to taper glucocorticoid therapy [<a href="#rid57">57</a>]. However, nearly half of these patients had not received prior treatment with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> which is now a key component of the initial therapy for acute pericarditis. Small case series suggest that <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may be helpful in patients with recurrent pericarditis refractory to other therapies [<a href="#rid58">58,59</a>].</p><p>Limited evidence suggests that <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil may be effective in patients with recurrent pericarditis not responsive to glucocorticoid therapy, glucocorticoid-dependent, or with intolerable glucocorticoid side effects [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H3104904671"><span class="h2">Role of pericardiectomy</span><span class="headingEndMark"> — </span>Pericardiectomy is an option for patients with recurrent pericarditis who have persistent symptoms after failure of medical regimens including NSAID or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and glucocorticoid. In this setting, the potential benefits and risks of fourth-line drug regimens and of pericardiectomy (as an alternative to drug therapy) are discussed with the patient. The 2015 ESC guidelines recommend pericardiectomy as a last option in patients that are refractory to all medical therapies [<a href="#rid14">14</a>]. However, in individuals with ongoing symptoms and relapses in spite of medical therapy, pericardiectomy appears to be a safe and frequently effective treatment option which can spare months to years of immunosuppression when performed at experienced centers.</p><p>The largest reported cohort of patients with chronic recurrent pericarditis (mean six to seven relapses) included 184 patients treated at a single referral center from 1994 through 2005, with significant baseline differences noted between the two groups (patients in the surgical group had more relapses [6.9 versus 5.5 in the medical treatment group] and were more likely to have been taking <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or glucocorticoid) [<a href="#rid61">61</a>]. Surgery for pericardiectomy appears to be safe, with no deaths and only two major complications (one stroke, one episode of bleeding requiring reoperation) in the immediate postoperative period and no significant difference in all-cause mortality over an average follow-up of 5.5 years. Additionally, patients treated with surgical pericardiectomy had significantly fewer relapses (9 versus 29 percent in the medical treatment group).</p><p>One concern is the prospect of impaired wound healing when sternotomy is performed in patients who have had a prolonged exposure to high doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. However, glucocorticoid use is not an absolute contraindication to proceeding with pericardiectomy. Glucocorticoids can be tapered relatively quickly after the procedure.</p><p class="headingAnchor" id="H13"><span class="h2">Recurrent pain without objective evidence of disease</span><span class="headingEndMark"> — </span>A difficult management problem is presented by the patient who reports recurrence of pain, but in whom no clinical or laboratory evidence of pericarditis can be elicited. This problem is most likely to occur in more chronic cases in which numerous recurrences have been suppressed by <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid39">39</a>]. The cause of this phenomenon is unknown, but the need to withhold prednisone is clear. The problem is further complicated by the fact that, in some patients who are having a recurrence, pain precedes objective evidence of pericarditis.</p><p>It is necessary to explain to the patient that the pain may not be a manifestation of recurrence. However, patients who have experienced frequent recurrences may be hard to convince; as a result, it is important to carefully describe the clinical dilemma and explain the need to stop <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or not to start a new course of glucocorticoid therapy.</p><p>Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The pain is treated by simple analgesic remedies, and glucocorticoids are avoided for five to seven days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient is then reexamined, and ECG, chest radiograph, echocardiogram, erythrocyte sedimentation rate, CRP, and white blood cell count are obtained [<a href="#rid3">3</a>]. CMR imaging with delayed enhancement may be considered if the diagnosis remains uncertain after the above testing, as it is highly sensitive for pericardial inflammation. Signs of pericarditis that qualify for establishment of the diagnosis include pericardial rubs, ECG changes, a pericardial effusion, and pericardial inflammation shown by CMR. An otherwise unexplained elevation in serum CRP is also suggestive of recurrent pericarditis in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If signs of pericarditis are present, another course of treatment as outlined above is begun.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is no objective evidence of pericarditis, the patient is told that, although the pain is indistinguishable from that of previous episodes, pericarditis is no longer present and that it is not known why the pain has recurred. Pain management should be initiated at this point.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain management begins with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, but more potent analgesics can be given, if necessary. If the pain is still not controlled, the patient is referred to a pain clinic with periodic monitoring for pericarditis.</p><p></p><p class="headingAnchor" id="H2235568"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H3446869799"><span class="h2">General prognosis</span><span class="headingEndMark"> — </span>Overall prognosis is excellent for most patients with idiopathic recurrent pericarditis, although quality of life can be severely affected in patients with recurrent, incessant, or chronic pericarditis. Severe complications are uncommon even with multiple recurrences [<a href="#rid1">1-3,9,13,23,24,62</a>].</p><p>Though symptoms associated with recurrent pericarditis can be uncomfortable and alter a patient's quality of life, the overall prognosis is generally good, and life-threatening complications (eg, cardiac tamponade, constrictive pericarditis) only rarely develop, although subclinical constrictive physiology may be evident in some patients on echocardiographic examination.</p><p class="headingAnchor" id="H2414189840"><span class="h2">Risk of constrictive pericarditis</span><span class="headingEndMark"> — </span>One of the most worrisome potential complications is evolution toward constrictive pericarditis. A common belief is that the risk of constrictive pericarditis may be related to the number of recurrences, although it has been well demonstrated that the risk is essentially related to the etiology: high risk for bacterial pericarditis (tuberculous and purulent), intermediate risk for immune-mediated and neoplastic pericarditis, low risk for viral pericarditis, and no known risk for idiopathic recurrent pericarditis [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H3042773425"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16976.html" rel="external">"Patient education: Pericarditis in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3427.html" rel="external">"Patient education: Pericarditis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7605049"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Recurrent pericarditis, which occurs in up to one-third of patients following a previous attack of acute pericarditis, is characterized by return of symptoms of acute pericarditis after a symptom-free interval of at least four to six weeks. The recurrence of symptoms can be at any point following the cessation of acute pericarditis symptoms, but usually occurs weeks to months later. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Most cases of recurrent pericarditis are likely caused by an autoimmune process, although a minority of cases may be due to viral infection. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – The presenting symptoms of recurrent pericarditis are generally similar to those for acute pericarditis, although the presenting symptoms are frequently less intense during recurrences. The most frequent symptom of recurrent pericarditis is pleuritic chest pain. (See <a class="local">'Key features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Recurrent pericarditis is diagnosed in a patient with a prior episode of acute pericarditis who develops recurrent symptoms (typically pleuritic chest pain) and at least one sign of pericardial inflammation (fever, pericardial rub, characteristic electrocardiogram changes, new or worsening pericardial effusion, elevation of an inflammatory marker, or evidence of pericardial inflammation on cardiovascular magnetic resonance or computed tomography) after an at least four- to six-week symptom-free interval  (<a class="graphic graphic_table graphicRef64302" href="/z/d/graphic/64302.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – General management of recurrent pericarditis includes effective communication with and education of the patient about the expected disease course and importance of treatment adherence, including the role of activity restriction to avoid recurrence. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapy</strong> – The following approach is for nonpregnant patients with recurrent pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>)(see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For most patients with recurrent pericarditis, we recommend combination therapy with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> plus either a nonsteroidal antiinflammatory drug (NSAID) or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>), rather than NSAID alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We treat most patients with <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> plus colchicine, although acceptable alternatives are aspirin plus colchicine or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> plus colchicine  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). The duration of therapy is generally at least one month and is guided by the time to resolution of symptoms and normalization of inflammatory biomarkers. (See <a class="local">'NSAID or aspirin'</a> above and <a class="local">'Colchicine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid</strong><strong> plus </strong><strong>colchicine</strong> – For patients with recurrent pericarditis with persistent symptoms on <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> plus NSAID (or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) or who have a contraindications to NSAID and aspirin therapy, we suggest treatment with glucocorticoid therapy plus colchicine (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use moderate initial dosing (eg, 0.2 to 0.5 mg/kg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) followed by a slow taper (rather than high doses with a rapid taper)  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Triple therapy</strong> – For patients with persistent symptoms on dual therapy with glucocorticoid therapy plus <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, we suggest addition of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy (triple therapy)  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fourth line therapy</strong> – For patients with recurrent pericarditis with persistent symptoms despite third-line therapy, we treat based upon whether an inflammatory phenotype is present. In this setting, the potential benefits and risks of immune therapy, and of pericardiectomy as an alternative, are discussed with the patient. (See <a class="local">'Role of pericardiectomy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with an inflammatory phenotype (see <a class="local">'Inflammatory phenotype'</a> above), we suggest an interleukin 1 inhibitor (<a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a> or <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>)  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Interleukin 1 inhibitors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a noninflammatory phenotype, options include intravenous immunoglobulin (preferred for patients with an autoimmune disorder) and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (preferred for patients with no identified autoimmune disorder)  (<a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">table 2</a>). (See <a class="local">'Other immune therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of pericardiectomy</strong> – Pericardiectomy is an option for patients with recurrent pericarditis after failure of medical regimens including NSAID (or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>), <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and glucocorticoid. Pericardiectomy is an effective therapy which can spare months to years of immunosuppression when performed at experienced centers. (See <a class="local">'Our approach'</a> above and <a class="local">'Role of pericardiectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The overall prognosis for most patients with idiopathic recurrent pericarditis is excellent, with only a minority of patients having a recurrent, incessant, or chronic course. The risk of developing constrictive pericarditis is low for patients with viral or idiopathic recurrent pericarditis. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Robinson J, Brigden W. Recurrent pericarditis. Br Med J 1968; 2:272.</a></li><li><a class="nounderline abstract_t">Fowler NO. Recurrent pericarditis. Cardiol Clin 1990; 8:621.</a></li><li><a class="nounderline abstract_t">Fowler NO, Harbin AD 3rd. Recurrent acute pericarditis: follow-up study of 31 patients. J Am Coll Cardiol 1986; 7:300.</a></li><li><a class="nounderline abstract_t">Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.</a></li><li><a class="nounderline abstract_t">Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75:76.</a></li><li><a class="nounderline abstract_t">Andreis A, Imazio M, Casula M, et al. Recurrent pericarditis: an update on diagnosis and management. Intern Emerg Med 2021; 16:551.</a></li><li><a class="nounderline abstract_t">Maisch B, Ristić AD, Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 2002; 23:1503.</a></li><li><a class="nounderline abstract_t">Spodick DH. Intrapericardial treatment of persistent autoreactive pericarditis/myopericarditis and pericardial effusion. Eur Heart J 2002; 23:1481.</a></li><li><a class="nounderline abstract_t">Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart 2004; 90:1364.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004; 43:1042.</a></li><li><a class="nounderline abstract_t">Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112:2012.</a></li><li><a class="nounderline abstract_t">Imazio M, Pivetta E, Andreis A, et al. Incessant Pericarditis as a Risk Factor for Complicated Pericarditis and Hospital Admission. Circulation 2021; 143:401.</a></li><li><a class="nounderline abstract_t">Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol 2006; 98:267.</a></li><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li><a class="nounderline abstract_t">Cantarini L, Lucherini OM, Brucato A, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 2012; 101:525.</a></li><li><a class="nounderline abstract_t">Peet CJ, Rowczenio D, Omoyinmi E, et al. Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. J Am Heart Assoc 2022; 11:e024931.</a></li><li><a class="nounderline abstract_t">Pankuweit S, Wädlich A, Meyer E, et al. Cytokine activation in pericardial fluids in different forms of pericarditis. Herz 2000; 25:748.</a></li><li><a class="nounderline abstract_t">Maisch B. Recurrent pericarditis: mysterious or not so mysterious? Eur Heart J 2005; 26:631.</a></li><li><a class="nounderline abstract_t">DeLine JM, Cable DG. Clustering of recurrent pericarditis with effusion and constriction in a family. Mayo Clin Proc 2002; 77:39.</a></li><li><a class="nounderline abstract_t">Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA 2015; 314:1498.</a></li><li><a class="nounderline abstract_t">Raatikka M, Pelkonen PM, Karjalainen J, Jokinen EV. Recurrent pericarditis in children and adolescents: report of 15 cases. J Am Coll Cardiol 2003; 42:759.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Adler Y, et al. Prognosis of idiopathic recurrent pericarditis as determined from previously published reports. Am J Cardiol 2007; 100:1026.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Management, risk factors, and outcomes in recurrent pericarditis. Am J Cardiol 2005; 96:736.</a></li><li><a class="nounderline abstract_t">Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005; 165:1987.</a></li><li><a class="nounderline abstract_t">Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med 2004; 351:2195.</a></li><li><a class="nounderline abstract_t">Imazio M, Pivetta E, Palacio Restrepo S, et al. Usefulness of Cardiac Magnetic Resonance for Recurrent Pericarditis. Am J Cardiol 2020; 125:146.</a></li><li><a class="nounderline abstract_t">Chetrit M, Xu B, Kwon DH, et al. Imaging-Guided Therapies for Pericardial Diseases. JACC Cardiovasc Imaging 2020; 13:1422.</a></li><li><a class="nounderline abstract_t">Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2013; 26:965.</a></li><li><a class="nounderline abstract_t">Alraies MC, AlJaroudi W, Yarmohammadi H, et al. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am J Cardiol 2015; 115:542.</a></li><li><a class="nounderline abstract_t">Antonopoulos AS, Vrettos A, Androulakis E, et al. Cardiac magnetic resonance imaging of pericardial diseases: a comprehensive guide. Eur Heart J Cardiovasc Imaging 2023; 24:983.</a></li><li><a class="nounderline abstract_t">Imazio M, Andreis A, Agosti A, et al. Usefulness of Beta-Blockers to Control Symptoms in Patients With Pericarditis. Am J Cardiol 2021; 146:115.</a></li><li><a class="nounderline abstract_t">Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:712.</a></li><li><a class="nounderline abstract_t">Markel G, Imazio M, Brucato A, Adler Y. Prevention of recurrent pericarditis with colchicine in 2012. Clin Cardiol 2013; 36:125.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011; 155:409.</a></li><li><a class="nounderline abstract_t">Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014; 383:2232.</a></li><li><a class="nounderline abstract_t">Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord 2019; 19:207.</a></li><li><a class="nounderline abstract_t">Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005; 26:723.</a></li><li><a class="nounderline abstract_t">Imazio M, Demichelis B, Parrini I, et al. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am J Cardiol 2004; 94:973.</a></li><li><a class="nounderline abstract_t">Godeau P, Derrida JP, Bletry O, Herreman G. [Recurrent acute pericarditis and corticoid dependence. Apropos of 10 cases]. Sem Hop 1975; 51:2393.</a></li><li><a class="nounderline abstract_t">Marcolongo R, Russo R, Laveder F, et al. Immunosuppressive therapy prevents recurrent pericarditis. J Am Coll Cardiol 1995; 26:1276.</a></li><li><a class="nounderline abstract_t">Scardapane A, Brucato A, Chiarelli F, Breda L. Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis. Pediatr Cardiol 2013; 34:1989.</a></li><li><a class="nounderline abstract_t">Vassilopoulos D, Lazaros G, Tsioufis C, et al. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol 2012; 160:66.</a></li><li><a class="nounderline abstract_t">Picco P, Brisca G, Traverso F, et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60:264.</a></li><li><a class="nounderline abstract_t">Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis. Am J Cardiol 2015; 116:1277.</a></li><li><a class="nounderline abstract_t">Imazio M. Anti-IL-1 agents: a paradigm shift in medical therapy for recurrent pericarditis? Heart 2020.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Belli R, et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2014; 15:840.</a></li><li><a class="nounderline abstract_t">Lazaros G, Imazio M, Brucato A, et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J Cardiovasc Med (Hagerstown) 2016; 17:256.</a></li><li><a class="nounderline abstract_t">Klein AL, Imazio M, Cremer P, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med 2021; 384:31.</a></li><li class="breakAll">https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-disease-causes-recurrent-inflammation-sac-surrounding-heart? (Accessed on March 26, 2021).</li><li><a class="nounderline abstract_t">Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA 2016; 316:1906.</a></li><li><a class="nounderline abstract_t">Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol 2020; 27:956.</a></li><li><a class="nounderline abstract_t">Kougkas N, Fanouriakis A, Papalopoulos I, et al. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford) 2018; 57:1494.</a></li><li><a class="nounderline abstract_t">Epçaçan S, Sahin S, Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab. Cardiol Young 2019; 29:549.</a></li><li><a class="nounderline abstract_t">Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev 2021; 20:102763.</a></li><li><a class="nounderline abstract_t">Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. J Am Coll Cardiol 2023; 82:30.</a></li><li><a class="nounderline abstract_t">Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol 2011; 147:477.</a></li><li><a class="nounderline abstract_t">Moretti M, Buiatti A, Merlo M, et al. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am J Cardiol 2013; 112:1493.</a></li><li><a class="nounderline abstract_t">Tona F, Bellotto F, Laveder F, et al. Efficacy of high-dose intravenous immunoglobulins in two patients with idiopathic recurrent pericarditis refractory to previous immunosuppressive treatment. Ital Heart J 2003; 4:64.</a></li><li><a class="nounderline abstract_t">Peiffer-Smadja N, Domont F, Saadoun D, Cacoub P. Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. Autoimmun Rev 2019; 18:621.</a></li><li><a class="nounderline abstract_t">Khandaker MH, Schaff HV, Greason KL, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc 2012; 87:1062.</a></li><li><a class="nounderline abstract_t">Brucato A, Brambilla G, Adler Y, et al. Therapy for recurrent acute pericarditis: a rheumatological solution? Clin Exp Rheumatol 2006; 24:45.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 2011; 124:1270.</a></li></ol></div><div id="topicVersionRevision">Topic 4944 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5646538" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2249216" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944348" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recurrent acute pericarditis: follow-up study of 31 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001332" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31918837" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33641044" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrent pericarditis: an update on diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242070" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242064" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intrapericardial treatment of persistent autoreactive pericarditis/myopericarditis and pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486149" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Relapsing pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028364" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Day-hospital treatment of acute pericarditis: a management program for outpatient therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186437" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33493032" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incessant Pericarditis as a Risk Factor for Complicated Pericarditis and Hospital Admission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16828606" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term outcomes in difficult-to-treat patients with recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22311714" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35658515" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11200123" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cytokine activation in pericardial fluids in different forms of pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755754" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recurrent pericarditis: mysterious or not so mysterious?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794456" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clustering of recurrent pericarditis with effusion and constriction in a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26461998" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation and Treatment of Pericarditis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932616" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recurrent pericarditis in children and adolescents: report of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826391" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prognosis of idiopathic recurrent pericarditis as determined from previously published reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125506" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management, risk factors, and outcomes in recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186468" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548780" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical practice. Acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711636" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Usefulness of Cardiac Magnetic Resonance for Recurrent Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31734199" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Imaging-Guided Therapies for Pericardial Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23998693" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25547939" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37207354" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cardiac magnetic resonance imaging of pericardial diseases: a comprehensive guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539856" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Usefulness of Beta-Blockers to Control Symptoms in Patients With Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177006" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Controversial issues in the management of pericardial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736783" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23404655" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevention of recurrent pericarditis with colchicine in 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873705" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Colchicine for recurrent pericarditis (CORP): a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694983" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31477020" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755753" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464694" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/175486" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : [Recurrent acute pericarditis and corticoid dependence. Apropos of 10 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594043" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunosuppressive therapy prevents recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052671" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of an interleukin-1βreceptor antagonist (anakinra) in idiopathic recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704870" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116906" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26279106" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33361397" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anti-IL-1 agents: a paradigm shift in medical therapy for recurrent pericarditis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25000255" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26090915" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200890" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200890" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27825009" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31610707" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30060102" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30931868" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33482337" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Interleukin 1α: a comprehensive review on the role of IL-1αin the pathogenesis and treatment of autoimmune and inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37380301" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296434" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Azathioprine in isolated recurrent pericarditis: a single centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23972350" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690925" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of high-dose intravenous immunoglobulins in two patients with idiopathic recurrent pericarditis refractory to previous immunosuppressive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30959210" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127733" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pericardiectomy vs medical management in patients with relapsing pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16539818" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Therapy for recurrent acute pericarditis: a rheumatological solution?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844077" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk of constrictive pericarditis after acute pericarditis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
